American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy

American Gastroenterological Association Institute Clinical Guidelines Committee; K Rajender Reddy; Kimberly L Beavers; Sarah P Hammond; Joseph K Lim; Yngve T Falck-Ytter; David S. Weinberg

doi:10.1053/j.gastro.2014.10.039

American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy

American Gastroenterological Association Institute Clinical Guidelines Committee
, K Rajender Reddy
, Kimberly L Beavers
, Sarah P Hammond
, Joseph K Lim
, Yngve T Falck-Ytter
, David S. Weinberg

University of Pennsylvania
Medical University of South Carolina
Dana-Farber Cancer Institute and Harvard Medical School
Yale University School of Medicine
Case Western Reserve University

Research output: Contribution to journal › Review article › peer-review

596 Scopus citations

Original language	English
Pages (from-to)	215-9; quiz e16-7
Number of pages	5
Journal	Gastroenterology
Volume	148
Issue number	1
DOIs	https://doi.org/10.1053/j.gastro.2014.10.039
State	Published - Dec 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Antiviral Agents/therapeutic use
Biomarkers/blood
DNA, Viral/blood
Hepatitis B/diagnosis
Hepatitis B Antibodies/blood
Hepatitis B Surface Antigens/blood
Hepatitis B virus/drug effects
Humans
Immunosuppressive Agents/adverse effects
Recurrence
Treatment Outcome
Viral Load
Virus Activation/drug effects

Access to Document

10.1053/j.gastro.2014.10.039

Cite this

American Gastroenterological Association Institute Clinical Guidelines Committee, Reddy, K. R., Beavers, K. L., Hammond, S. P., Lim, J. K., Falck-Ytter, Y. T., & Weinberg, D. S. (2015). American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology, 148(1), 215-9; quiz e16-7. https://doi.org/10.1053/j.gastro.2014.10.039

@article{f34c89aea9554a98b20300f610384140,

title = "American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy",

keywords = "Antiviral Agents/therapeutic use, Biomarkers/blood, DNA, Viral/blood, Hepatitis B/diagnosis, Hepatitis B Antibodies/blood, Hepatitis B Surface Antigens/blood, Hepatitis B virus/drug effects, Humans, Immunosuppressive Agents/adverse effects, Recurrence, Treatment Outcome, Viral Load, Virus Activation/drug effects",

author = "\{American Gastroenterological Association Institute Clinical Guidelines Committee\} and Reddy, \{K Rajender\} and Beavers, \{Kimberly L\} and Hammond, \{Sarah P\} and Lim, \{Joseph K\} and Falck-Ytter, \{Yngve T\} and Weinberg, \{David S.\}",

year = "2015",

month = dec,

doi = "10.1053/j.gastro.2014.10.039",

language = "English",

volume = "148",

pages = "215--9; quiz e16--7",

journal = "Gastroenterology",

issn = "0016-5085",

publisher = "W.B. Saunders",

number = "1",

}

American Gastroenterological Association Institute Clinical Guidelines Committee, Reddy, KR, Beavers, KL, Hammond, SP, Lim, JK, Falck-Ytter, YT & Weinberg, DS 2015, 'American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy', Gastroenterology, vol. 148, no. 1, pp. 215-9; quiz e16-7. https://doi.org/10.1053/j.gastro.2014.10.039

American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. / American Gastroenterological Association Institute Clinical Guidelines Committee; Reddy, K Rajender; Beavers, Kimberly L et al.
In: Gastroenterology, Vol. 148, No. 1, 12.2015, p. 215-9; quiz e16-7.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy

AU - American Gastroenterological Association Institute Clinical Guidelines Committee

AU - Reddy, K Rajender

AU - Beavers, Kimberly L

AU - Hammond, Sarah P

AU - Lim, Joseph K

AU - Falck-Ytter, Yngve T

AU - Weinberg, David S.

PY - 2015/12

Y1 - 2015/12

KW - Antiviral Agents/therapeutic use

KW - Biomarkers/blood

KW - DNA, Viral/blood

KW - Hepatitis B/diagnosis

KW - Hepatitis B Antibodies/blood

KW - Hepatitis B Surface Antigens/blood

KW - Hepatitis B virus/drug effects

KW - Humans

KW - Immunosuppressive Agents/adverse effects

KW - Recurrence

KW - Treatment Outcome

KW - Viral Load

KW - Virus Activation/drug effects

UR - https://www.scopus.com/pages/publications/84922953411

U2 - 10.1053/j.gastro.2014.10.039

DO - 10.1053/j.gastro.2014.10.039

M3 - Review article

C2 - 25447850

SN - 0016-5085

VL - 148

SP - 215-9; quiz e16-7

JO - Gastroenterology

JF - Gastroenterology

IS - 1

ER -

American Gastroenterological Association Institute Clinical Guidelines Committee, Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015 Dec;148(1):215-9; quiz e16-7. doi: 10.1053/j.gastro.2014.10.039

American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this